Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations
Katie S. Gatwood(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Karin Abernathy(Centennial Medical Center), Stacy Pak(City Of Hope National Medical Center), Brittney Baer(Vanderbilt University Medical Center), Zahra Mahmoudjafari(The University of Kansas Cancer Center), Brian Lee(City Of Hope National Medical Center), Hoim Kim(City Of Hope National Medical Center)
Cited by 21
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782